Catv band dual output modulator

COMMUNICATIONS COMPONENTS
CATV Band Dual Output Modulator
Key Features
• Flat frequency response
• Two optical output ports
• Integrated phase modulator
• High optical damage threshold
Applications
The JDSU community antenna television (CATV) band dual output modulator iswidely accepted for use in externally modulated 1550 nm transmitters. Two optical outputs offer flat frequency response and excellent composite second order distortion (CSO) performance. This product is rated for operation atoptical power levels to 200 mW.
A dedicated production line and strict process control measures ensure minimalvariation in device-to-device characteristics.
Typical Frequency Response, S21
Typical Return Loss Curve, S11
NORTH AMERICA: 800 498-JDSU (5378)
WORLDWIDE: +800 5378-JDSU
WEBSITE: www.jdsu.com
CATV BAND DUAL OUTPUT MODULATOR
CATV Band Dual Output Modulator
Schematic

CATV Band Dual Output Modulator
(Specifications in inches [mm] unless otherwise noted.) Dimensions Diagram
CATV BAND DUAL OUTPUT MODULATOR
Specifications
Parameter
Specification
General
Material Lithium
Optical1
Operating wavelength
Electrical1
Intensity modulator
Passive bias point, relative to quadrature, at 1550 nm Mechanical
Input fiber
Fujikura SM 15-P-8/125-UV/UV-400, 70 cm minimumHytrel 900 µm loose tube, 12 inches SMF-28, 95 cm minimumHytrel 900 µm loose tube 12 inches Environmental
Operating temperature
1. All measurements made at 23°C unless otherwise noted.
2. Insertion loss is measured at the maximum of the modulator’s transfer function and does not include the 3 dB loss incurred when operated at quadrature.
3. The bias point of this device is most stable when operated with applied DC voltage close to 0 V.
4. For an 80 channel NTSC, 3% OMI CATV link, with correctly operating modulator bias control, 0.26° delta phase yields a maximum of 68 dBc CSO on both outputs.
CATV BAND DUAL OUTPUT MODULATOR
Ordering Information
For more information on this or other products and their availability, please contact your local JDSU account manager orJDSU directly at 1-800-498-JDSU (5378) in North America and +800-5378-JDSU worldwide or via e-mail atcustomer.service@jdsu.com.
Sample: 10020476
Product Code
Description
APE is a trademark of JDSU.
Hytrel is a registered trademark of E. I. du Pont de Nemours and Company.
SMF-28 and Fujikura SM-P-8/125-UV-400 are registered trademarks of Corning Incorporated.
All statements, technical information and recommendations related to the products herein are based upon information believed to bereliable or accurate. However, the accuracy or completeness thereof is not guaranteed, and no responsibility is assumed for any inaccuracies. The user assumes all risks and liability whatsoever in connection with the use of a product or its application. JDSU reservesthe right to change at any time without notice the design, specifications, function, fit or form of its products described herein, includingwithdrawal at any time of a product offered for sale herein. JDSU makes no representations that the products herein are free from any intellectual property claims of others. Please contact JDSU for more information. JDSU and the JDSU logo aretrademarks of JDS Uniphase Corporation. Other trademarks are the property of their respective holders. 2006 JDS UniphaseCorporation. All rights reserved. 10133791 Rev. 001 05/06 CATVBDOM.DS.CC.AE NORTH AMERICA: 800 498-JDSU (5378)
WORLDWIDE: +800 5378-JDSU
WEBSITE: www.jdsu.com

Source: http://wircom.com.ua/content/1791/catvbdomdsccae05.pdf

Farmaceutico_ma.p65

CONHECIMENTOS GERAIS 04. O princípio da rede regionalizada e hierarquizada de servi- 01. De acordo com a Constituição Federal: Título VIII – Cap II, Seção II – Saúde, compete ao sistema único de saúde –(A) responsabilização dos municípios pela atenção primá-ria, dos estados pela atenção secundária e da esferafederal pelas instituições de ensino superior e de as

Programme atc- eric thervet

Programme ATC- Yannick LE MEUR Sunday Concurrent Session: Kidney Immunosuppression: CNI Minimization – Avoidance Protocols 16h00 [129] Efficacy and Safety of Mycophenolate Mofetil (MMF)/Sirolimus (SRL) Maintenance Therapy after Calcineurin Inhibitor (CNI) Withdrawal in Renal Transplant Recipients: Final Results of the Spare-the-Nephron (STN) Trial. [130] Analysis of Allospe

© 2010-2017 Pharmacy Pills Pdf